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Abstract
Background: Recently completed clinical trials have shown that certain interventions improve the outcome of the
critically ill. To facilitate the implementation of these interventions, professional organizations have developed guidelines.
Although the impacts of the individual evidence-based interventions have been well described, the overall impact on
outcome of introducing multiple evidence-based protocols has not been well studied. The objective of this study was to
determine the impact of introducing multiple evidence-based protocols on patient outcome.
Methods: A retrospective, cohort study of 8,386 patients admitted to the medical intensive care unit (MICU) of an
academic, tertiary medical center, from January 2000 through June 2005 was performed. Four evidence-based protocols
(lung protective strategy for acute lung injury, activated protein C for severe sepsis/septic shock, intravenous insulin for
hyperglycemia control and a protocol for sedation/analgesia) were introduced in the MICU between February 2002 and
April 2004. We considered the time from January 2000 through January 2002 as the pre-protocol period, from February
2002 through March 2004 as the transition period and from April 2004 through June 2005 as the protocol period. We
retrieved data including demographics, severity of illness as measured by the Acute Physiology and Chronic Health
Evaluation (APACHE) III, MICU length of stay and hospital mortality. Student's t, Kruskal-Wallis, Mann-Whitney U, chi
square and multiple logistic regression analyses were used to compare differences between groups. P-values < 0.05 were
considered significant.
Results: The predicted mean mortality rates were 20.7%, 21.1% and 21.8%, with the observed mortality rates of 19.3%,
18.0% and 16.9% during the pre-protocol, transition and protocol periods, respectively. Using the pre-protocol period
as a reference, the severity-adjusted risk (95% confidence interval) of dying was 0.777 (0.655 – 0.922) during the protocol
period (P = 0.0038). The average 28-day MICU free days improved during the protocol period compared to the pre-
protocol period. The benefit was limited to sicker patients and those who stayed in the MICU longer.
Conclusion: The introduction of multiple evidence-based protocols is associated with improved outcome in critically
ill medical patients.
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Background
Although the numbers of acute care hospitals and hospi-
tal beds have declined over the last two decades, the
number of intensive care unit (ICU) beds has risen [1].
Despite the proliferation of intensive care units, there had
not been compelling evidence to guide critical care prac-
tice until recent randomized clinical trials showed that
certain clinical practices improve the outcome of the crit-
ically ill. The daily interruption of intravenous sedative
medications in patients receiving invasive mechanical
ventilation reduces the length of ICU stay and the dura-
tion of mechanical ventilation [2]. Early goal-directed
therapy for severe sepsis and septic shock [3], lung protec-
tive strategy for acute lung injury (ALI) [4], control of
hyperglycemia using intravenous insulin [5,6] and the use
activated protein C for severe sepsis [7] reduce the mor-
bidity and mortality of critically ill patients.
Although there is ample evidence supporting the benefit
that certain interventions improve the clinical outcome of
the critically ill, including length of stay, duration of
mechanical ventilation, and mortality, there are barriers
to translating the evidence into clinical practice [8-10]. To
overcome these barriers, professional organizations
[11,12] and individual medical centers [13-16] have
developed international and local guidelines and proto-
cols based on the available evidence. Federal and state
governments, insurers and accreditation bodies have also
reached a consensus recognizing the importance of evi-
dence based practice and quality measurement [17]. Cur-
rently, the Centers for Medicare and Medicaid Services are
developing and implementing a set of pay-for-perform-
ance initiatives to support quality improvement in the
care of Medicare and Medicaid beneficiaries in the Unites
States of America [18].
Although the impacts of the individual evidence-based
interventions have been well described, the overall impact
on outcome of introducing multiple evidence-based pro-
tocols has not been well studied. We have implemented
multiple, evidence-based protocols in our medical inten-
sive care unit (MICU) in the last 4 years. We have an Acute
Physiology and Chronic Health Evaluation (APACHE) III
database that is used for severity adjusted outcome meas-
ure including mortality and length of stay [19]. We intro-
duced four evidence-based clinical protocols (lung
protective strategy for ALI, activated protein C for septic
shock, intravenous insulin for hyperglycemia control, and
sedation/analgesia protocol) in the MICU between Febru-
ary 2002 and April 2004. This study assesses the impact of
introducing these evidence-based protocols on patient
outcome based on our APACHE III database.
Methods
In this retrospective, cohort study, we reviewed the
APACHE III database of patients admitted to the MICU of
Mayo Medical Center, Rochester, Minnesota. Mayo Medi-
cal Center is a tertiary, teaching institution with two hos-
pitals comprising approximately 1,900 in-patient beds.
The study was approved by the Mayo Foundation Institu-
tional Review Board. The MICU was a closed unit
throughout the study period. It had a 15-bed capacity at
the beginning of the study period. The capacity was
increased to 19-bed in August 2002 and 24-bed in Decem-
ber 2002. A critical care service team consisting of attend-
ing intensivists, critical care fellows, residents,
pharmacists, nurses and respiratory therapists staffed the
MICU. The non-physician staffing was consistent
throughout the study period. The nurse to patient ratio
was 1 to 1 or 1 to 2. Nurses, pharmacists and respiratory
therapists participated during the daily rounds. All attend-
ing intensivists had internal medicine background and
critical care or pulmonary/critical care subspecialty train-
ing. Fellows and internal medicine residents provided 24-
hour in-house coverage. The attending intensivists did not
routinely stay in-house at night but were available by
phone and came to the ICU as needed. Clinically impor-
tant decisions in the ICU were made by, or under the
direct supervision of, the attending intensivists.
Patients who did not authorize their medical records to be
reviewed for research were excluded. Data retrieved
included demographics, MICU admission diagnosis;
Acute Physiology Score (APS), APACHE III score, and hos-
pital predicted mortality rate based on the first MICU day
values; length of MICU stay and hospital mortality. The
hospital predicted mortality rates were calculated based
on the admission diagnoses, APACHE III score and loca-
tion prior to MICU admission, using software provided by
Cerner Corporation (Kansas City, Missouri) [20]. Sub-
group analyses were performed based on the severity of
illness and the length of MICU stay. The severity of illness
was categorized into high and low using the median pre-
dicted hospital death as a cutoff point. The MICU length
of stay was categorized into long and short using the
median MICU length of stay as a cutoff point.
We developed and started implementing four evidence-
based protocols as follows: lung protective strategy for ALI
in February 2002, activated protein C for severe sepsis/
septic shock in October 2002, intravenous insulin for
hyperglycemia control in September 2003 and a protocol
for sedation/analgesia in April 2004. The protocols were
developed with the participation of all MICU staff includ-
ing physicians, nurses, respiratory therapists and pharma-
cists. The protocol for lung protective strategy was based
on providing tidal volume not greater than 6 mL/kg ideal
body weight in patients with ALI or Acute Respiratory Dis-BMC Emergency Medicine 2007, 7:10 http://www.biomedcentral.com/1471-227X/7/10
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tress syndrome (ARDS). The activated protein C protocol
was applicable for adults with severe sepsis/septic shock
and multiple organ failure with no risk factor for bleeding
and who opted for full resuscitation and life support. The
hyperglycemia control protocol was activated if patients'
glucose was > 150 mg/dL. A continuous intravenous insu-
lin infusion was titrated to maintain blood glucose level
between 100 and 119 mg/dL. There was also a protocol
for the treatment of hypoglycemia based on symptoms or
blood glucose level < 60 mg/dL. The sedation/analgesia
protocol had two parts, one for patients anticipated to
remain intubated for 48 hours or less and another proto-
col for those expected to remain intubated longer than 48
hours. The less than 48 hours sedations/analgesia proto-
col used morphine or fentanyl for analgesia and propofol
or midazolam for sedation. The longer than 48-hour pro-
tocol used morphine or fentanyl for analgesia and
lorazepam for sedation. Both analgesia/sedation proto-
cols used numeric pain scales and Richmond Agitation-
Sedation Scale (RASS) for titration and the continuous
infusion of the opioids and sedatives was interrupted
daily. (The sedation/analgesia protocols are available as
additional file 1 and 2.)
The development of each protocol had taken several
months before implementation. Once implemented, no
significant modifications were made in any one of the
protocols during the study period. We considered the
times from January 2000 through January 2002 as the pre-
protocol period, from February 2002 through March 2004
as the transition period (since introduction of the three
protocols started during this period) and from April 2004
through June 2005 as the protocol period (all four proto-
cols were implemented). During the pre-protocol period,
the implementation of evidence-based practice was based
on the individual physicians' knowledge and discretion.
During the development of the protocols, all MICU staff
became more familiar with the available evidence. With
the activation of the protocols, the elements that consti-
tute evidence-based practice were easily available in order-
set forms and were implemented with the active participa-
tion of intensivists, fellows, residents, nurses, respiratory
therapists and pharmacists.
The 28-day ICU free days were calculated by subtracting
the actual ICU length of stay in days from 28. The 28-day
ICU free day was considered 0 if a patient died before hos-
pital discharge or stayed in the ICU for > 28 days [21,22].
We used the 28-day ICU free days to avoid the confound-
ing effect of mortality. This number measured the time
interval that a patient was both alive and did not require
ICU support.
We summarized data as mean (standard deviation) (SD),
median (interquartile range) (IQR) or percentages. Stu-
dent's t, Kruskal-Wallis, Mann-Whitney U, and chi square
tests were used to compare differences between groups. In
order to determine the impact of the protocol on severity
adjusted patient outcome, we created a multiple logistic
regression model consisting of hospital mortality as a
dependent variable and the APACHE III predicted hospi-
tal mortality rate and the three study periods as independ-
ent variables. All independent variables were entered into
the model simultaneously. The pre-protocol period was
considered as reference in this logistic regression model.
When appropriate, the 95% confidence intervals (CI)
were calculated. We considered P values < 0.05 as statisti-
cally significant. We used StatView version 5.0 (SAS Inc,
Cary, North Carolina) and Confidence Interval Analysis
version 2.0.5 (Trevor Bryant, University of Southampton,
United Kingdom) computer softwares for statistical anal-
ysis. We used variable life-adjusted display (VLAD) to
show the differences between the cumulative and actual
deaths during the three periods of the study [23,24].
Results
After exclusion of 186 patients (2.2%) who did not
authorize their medical records to be reviewed for
research, 8,386 patients were included in the study. Of the
8,386 patients, 7,910 (94.3%) were white and 4,346
(51.8%) were male. Their mean (SD) age was 62.3 (19.1)
years. The mean APS, APACHE III score and predicted
hospital mortality rates were 46.5, 60.1 and 21.1%,
respectively. The number of patients included in the study
was 2,677 in the pre-protocol, 3,513 in the transition and
2,196 in the protocol periods (Table 1).
The protocol patients were older than the pre-protocol
patients (Table 1). Although the differences were small,
the APS, APACHE III score and predicted hospital mortal-
ity rate were higher in the protocol period compared to
the pre-protocol period (Table 1). Compared to the pre-
protocol group, the 28-day ICU free days were longer in
the protocol group (Table 2). Although the actual reduc-
tion was small, the logistic regression model showed that
the severity adjusted hospital mortality rate was signifi-
cantly reduced during the protocol period compared to
the pre-protocol period (Table 3). The VLAD shows an
overall improvement in mortality during the protocol
period (Figure 1).
The median predicted hospital death rate and ICU length
of stay were 11.8% and 1.6 days, respectively. The mortal-
ity benefit of the protocol period was limited to the high
severity and longer MICU stay groups (Table 4). There
were small differences in the 28-day ICU free days favor-
ing the protocol period compared to the pre-protocol
period in patients with higher severity of illness (Table 5).BMC Emergency Medicine 2007, 7:10 http://www.biomedcentral.com/1471-227X/7/10
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Discussion
In this study, we found that the introduction of multiple
evidence-based clinical practice protocols was associated
with a decline in severity-adjusted hospital mortality. We
also noted that the 28-day ICU free days improved
slightly. The benefits were limited to sicker patients and
those who had longer ICU stay. The study suggests that
the application of multiple evidence-based clinical prac-
tice protocols improves the clinical outcome of the criti-
cally ill.
Because of the complexity of intensive care units, the Insti-
tute for Healthcare Improvement (IHI) advocates use of
protocol-based bundles in order to apply the best availa-
ble science into clinical practice and improve patient out-
come [25]. In the current study, the introduction of
multiple evidence-based protocols was associated with
reducing the severity-adjusted risk of hospital death. There
are only few studies that addressed the impact of the
application of multiple protocols on the outcome of criti-
cally ill patients. Previous studies have shown that the
implementation of a ventilator bundle protocol (com-
posed of stress ulcer prophylaxis, deep vein thrombosis
prophylaxis, daily cessation of sedation and elevating the
patient's head at least 30 degrees above the horizontal
with or without daily assessment of readiness to wean
from mechanical ventilation) reduces the ICU length of
stay and duration of mechanical ventilation [13,26]. The
IHI has initiated the various phases of Saving Lives Cam-
paign. The campaign focuses on reducing mortality by
implementing evidence-based practices and reducing
errors. The findings in this study highlight the fact that
implementation of evidence-based clinical practice proto-
cols may help to achieve the objectives of the Saving Lives
Campaign.
In the Acute Respiratory Distress Syndrome Network
study, lung protective strategy reduced the mortality of
patients with ALI from 39.8% to 31.0% [4]. van den
Berghe and colleagues showed that intensive insulin ther-
apy reduced mortality of a predominantly surgical criti-
cally ill patient population from 10.9% to 7.2% [5]. In a
recent study of medical ICU patients by the same group,
the survival benefit of intensive insulin therapy was lim-
ited to patients who stay in the ICU for more than three
days [6]. In the overall MICU patient population, the hos-
pital mortality rate associated with intensive insulin ther-
apy (37.3%) was not statistically different from that of
conventional treatment (40.0%). However, in patients
who stayed in the medical ICU for more than three days,
intensive insulin therapy was associated with reducing the
hospital mortality rate from 52.5% to 43.0% [6]. In
patients with severe sepsis, recombinant human activated
protein C reduced the mortality rate from 30.8% to 24.7%
[7]. The reduction in mortality observed in our study is
consistent with the findings from the randomized clinical
trials. With regard to recombinant human activated pro-
tein C, recent observations suggest that only a minority of
eligible patients receive the treatment and it may have a
detrimental effect in certain subgroups of patients
[27,28].
The implications of reducing ICU days include reducing
ICU complications and associated costs. The study by
Kress and colleagues had shown reduction of ICU stay by
3.5 days using a protocol with daily interruption of seda-
tive infusions [2]. The 28-day ICU free days were longer in
Table 2: Difference in length of stay and hospital mortality among the three study periods
Outcome Pre-protocol N = 2,677 Transition N = 3,513 Protocol 2,196
Observed mortality, %, (95% CI) 19.3 (17.8 – 20.8) 18.0 (16.7 – 19.3) 16.9 (15.4 – 18.5)
ICU length of stay, days, median (IQR) 1.6 (0.85–3.29) 1.4 (0.84–2.98) * 1.7 (0.91–3.14)
28-day ICU free days, days, mean ± SD 20.4 ± 10.6 20.8 ± 10.3 21.1 ± 10.0*
CI = confidence interval; ICU = intensive care unit; IQR = interquartile range; SD = standard deviation
* P < 0.05 compared to pre-protocol period
Table 1: Difference in base-line characteristics among the three study periods*
Characteristics Pre-protocol N = 2,677 Transition N = 3,513 Protocol N = 2,196
Age, yrs, mean ± SD 61.7 ± 19.3 62.3 ± 19.0 63.0 ± 19.1†
Male sex 1,405 (52.5) 1,785 (50.8) 1,156 (52.6)
White race 2,526 (94.4) 3,306 (94.1) 2,078 (94.6)
APS, Median (IQR) 40 (25–59) 41 (27–59)† 43 (30–60)†
APACHE III, Median (IQR) 55 (37–76) 56 (39–75) 58 (42–77)†
Predicted mortality, %, Median (IQR) 11.3 (3.1–29.7) 11.5 (3.5–29.2) 13.0 (4.4–31.0)†
APS = Acute Physiology Score; APACHE = Acute Physiology and Chronic Health Evaluation; IQR = Interquartile range
*Values are number (percentage) unless indicated otherwise; †P < 0.05 compared to pre-protocol period.BMC Emergency Medicine 2007, 7:10 http://www.biomedcentral.com/1471-227X/7/10
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the protocol period in our study by 0.7 days. With the
shortage of staffed ICU beds in many medical centers,
reducing the ICU length of stay has important implica-
tions, by decreasing the associated cost and avoiding
delays in the care of patients waiting for ICU beds.
Although we did not implement the sedation/analgesia
protocol before 2004, it had been applied at the individ-
ual clinician's discretion, partly explaining why we did not
see the dramatic effect reported by Kress et al. In our ICU,
the critical care team made rounds at least twice daily.
Table 3: The association of the protocol periods with hospital mortality adjusted for the severity of illness
Variable Odds ratio (95% CI) P-value
Predicted mortality, % 1.049* (1.046 – 1.052) < 0.001
Study period
Pre-protocol Reference
Transition 0.869 (0.747–1.010) 0.067
Protocol 0.777 (0.655–0.922) 0.004
CI = Confidence interval
*This odds ratio reflects the risk of death per 1% rise in the predicted mortality rate for the entire study population.
Variable life-adjusted display (VLAD) for 8,386 patients consecutively admitted to the medical intensive care unit during the  three study periods (Pre-protocol, Transition, and Protocol) Figure 1
Variable life-adjusted display (VLAD) for 8,386 patients consecutively admitted to the medical intensive care unit during the 
three study periods (Pre-protocol, Transition, and Protocol).
Pre-protocol Transition ProtocolBMC Emergency Medicine 2007, 7:10 http://www.biomedcentral.com/1471-227X/7/10
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Even before the protocols were implemented, the critical
care consultants who guided daily care and the fellows
were aware of the studies that led to the protocols. In a
study by Krishnan et al from Johns Hopkins medical insti-
tute, protocol-directed weaning did not improve patient
outcome, including the ICU length of stay, compared to
the usual care in a closed, generously staffed medical
intensive care unit [29]. When the usual care is already
influenced by the available evidence and in intensive care
units where there is adequate physician staffing with daily
structured multi-disciplinary rounds, the benefits of the
protocols may not be as pronounced as in the original
studies.
Our study has several limitations. Since the study was per-
formed in a single medical center with its own unique
characteristics, the findings may not be generalizable. The
APACHE III database we used for the study did not
include information on the rate of compliance with the
protocols or evidence-based practice. We did not have the
data to determine the eligibility and contraindications for
each protocol. Our data also lacked the identification of
the individual patients who received treatment based on
the protocols. Since the four protocols were introduced at
various times of the study, it is not easy to determine the
effects of each protocol individually. We may not have
accounted for all confounding variables although we
adjusted for the severity of illness. Because of the retro-
spective design, our study cannot exclude the fact that
unmeasured changes in patient care and unrelated to the
protocols may have contributed to the improved out-
come. The current study was performed over a period of
Table 5: Difference in length of intensive care unit stay between the three study periods in severity subgroups of the study population
Subgroup and outcome Pre-protocol Transition Protocol
High severity of illness
ICU length of stay, days, median (IQR) 2.4 (1.13–5.02) 2.06 (1.05–4.64)* 2.4 (1.21–4.71)
28–day ICU free days, median (IQR) 23.2 (0.0–26.2) 24.1 (0.0–26.4) * 24.4 (0.0–26.3)*
Low severity of illness
ICU length of stay, days, median (IQR) 1.0 (0.75–1.99) 1.0 (0.72–1.93) 1.1 (0.77–1.99)
28-day ICU free days, median (IQR) 26.9 (25.9–27.3) 26.9 (26.0–27.3) 26.9 (25.9–27.2)
*P value < 0.05 compared to the pre-protocol period; ICU = intensive care unit; IQR = interquartile range; SD = standard deviation
Table 4: Subgroup analyses describing the association of the protocol periods with severity-adjusted hospital mortality
Subgroup Variable Odds ratio (95% CI) P-value
High severity of illness
Predicted mortality, % 1.040* (1.036 – 1.043) < 0.001
Protocol period
Pre-protocol Reference
Transition 0.831 (0.701–0.984) 0.031
Protocol 0.754 (0.625–0.910) 0.003
Low severity of illness
Predicted mortality, % 1.241* (1.191 – 1.293) < 0.001
Protocol period
Pre-protocol Reference
Transition 1.013 (0.730–1.406) 0.938
Protocol 0.733 (0.492–1.093 0.128
Long ICU length of stay
Predicted mortality, % 1.033* (1.029 – 1.036) < 0.001
Protocol period
Pre-protocol Reference
Transition 0.893 (0.746–1.069) 0.217
Protocol 0.745 (0.609–0.910) 0.004
Short ICU length of stay
Predicted mortality, % 1.077* (1.071 – 1.083) < 0.001
Protocol period
Pre-protocol Reference
Transition 0.829 (0.620–1.109) 0.207
Protocol 0.953 (0.686–1.325) 0.776
CI = Confidence interval
*This odds ratio reflects the risk of death per 1% rise in the predicted mortality rate for the entire study population.BMC Emergency Medicine 2007, 7:10 http://www.biomedcentral.com/1471-227X/7/10
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66 months. The transition period to having all the proto-
cols available in the MICU took 24 months. Because of
the long time interval it took to complete the study, we
cannot avoid the potential confounding effects of fre-
quently imperceptible changes in practice on outcome
measures. Our study did not control for factors such as
ICU and hospital patient volume and occupancy that may
influence outcome. In the early part of our study, there
were changes in the structure and staffing of the MICU.
The MICU had expanded from 15 to 19 and then to 24
beds and the intensivist to bed ratio had changed from
1:15 to 1:9.5 and then to 1:15 [30]. However, we had
shown these staffing and structural changes did not have
significant impact on mortality in a previous publication
[30]. Clinical researchers in our institution have moni-
tored practice patterns and published studies focusing on
ICU outcome in recent years. These reports may have had
a Hawthorne effect. The large number of patients in our
study may have led to statistically significant p values even
when the clinical differences are of limited clinical value.
For example, the difference in the 28-day ICU free days
between the pre-protocol and protocol period was only
0.7 although the P value was < 0.05.
Conclusion
The current study suggests that the introduction of several
evidence-based patient care protocols is associated with
improved (small albeit significant) severity adjusted mor-
tality in a population of critically ill adult patients admit-
ted to a medical ICU. Using sensitivity analysis, Pronovost
and colleagues have extrapolated that 167,819 lives can
be saved annually by the consistent and appropriate
implementation of evidence-based therapies in the inten-
sive care unit [31]. However, previous publications have
highlighted the delay and reluctance in translating
research findings into practice [8-10]. Errors of omission
should not be tolerated. Future studies should address the
barriers to the implementation of evidence-based clinical
practices in the ICU and the potential solutions to the bar-
riers.
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